Literature DB >> 5031746

Systemic candidiasis, a diagnostic challenge.

J M Hughes, J S Remington.   

Abstract

The serious and increasing problem of deep-seated Candida infection and the difficulties encountered in diagnosis of this entity prompted review of all well-documented cases of systemic candidiasis in a 39-month period at Stanford Medical Center. In only 19 of the 40. cases (47.5 percent) was the diagnosis suspected premortem; in 15 (37.5 percent) of these, the diagnosis was established. Thirty-three (82.5 percent) of the 40 patients died, and in 12 (39.4 percent) of them Candida infection was considered to be the primary cause of death or a major contributing factor. The seven survivors were treated either by specific chemotherapy or drainage of abscesses and empyema cavities. When the data were assessed in relation to underlying diseases and other possible predisposing factors, surgery was implicated in 50 percent of the total. In a study to define the prevalence of Candida in the saliva of patients with severe underlying illnesses receiving antibiotics or immunosuppressive therapy at the Stanford Medical Center, a significantly higher prevalence was noted in the multiple therapeutic modality group than in controls. In a review of reported data on methods for serological diagnosis of systemic candidiasis, only the precipitin and agglutinin methods appear promising.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5031746      PMCID: PMC1518336     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  44 in total

1.  INCIDENCE OF BRONCHOPULMONARY CANDIDIASIS IN PATIENTS TREATED WITH ANTIBIOTICS.

Authors:  S C CHAKRAVARTY; R S SANDHU
Journal:  Acta Tuberc Pneumol Scand       Date:  1964

2.  Candida albicans precipitins in respiratory disease in man.

Authors:  J Pepys; J A Faux; D S McCarthy; F E Hargreave
Journal:  J Allergy       Date:  1968-06

3.  Immune studies in candidiasis. 3. Precipitating antibodies in systemic candidiasis.

Authors:  C L Taschdjian; P J Kozinn; L Caroline
Journal:  Sabouraudia       Date:  1964-10

4.  Serum antibody titers to Candida albicans utilizing an immunofluorescent technic.

Authors:  N B Esterly
Journal:  Am J Clin Pathol       Date:  1968-09       Impact factor: 2.493

5.  Diagnosis and therapy of systemic candidiasis.

Authors:  P J Kozinn; C L Taschdjian; M S Seelig; L Caroline; A Teitler
Journal:  Sabouraudia       Date:  1969-06

6.  [Generalized candidiasis in panmyelophthisis].

Authors:  K W Ruprecht
Journal:  Mykosen       Date:  1969-01-01

7.  Serological evidence of Candida infection after open-heart surgery.

Authors:  I G Murray; H R Buckley; G C Turner
Journal:  J Med Microbiol       Date:  1969-11-04       Impact factor: 2.472

8.  Fungal infections complicating acute leukemia.

Authors:  G P Bodey
Journal:  J Chronic Dis       Date:  1966-06

9.  Serodiagnosis of systemic candidiasis.

Authors:  C L Taschdjian; P J Kozinn; A Okas; L Caroline; M A Halle
Journal:  J Infect Dis       Date:  1967-04       Impact factor: 5.226

10.  [Mycoses due to opportunistic fungi observed in the course of 1000 autopsies].

Authors:  A González-Mendoza; J Aguirre-García
Journal:  Sabouraudia       Date:  1967-06
View more
  5 in total

1.  Candida albicans abscess of lung.

Authors:  A H Rubin; G G Alroy
Journal:  Thorax       Date:  1977-06       Impact factor: 9.139

2.  Chemotherapy of experimental endogenous Candida albicans endophthalmitis.

Authors:  D B Jones
Journal:  Trans Am Ophthalmol Soc       Date:  1980

Review 3.  Candida infection in surgical patients.

Authors:  J S Solomkin; R L Simmons
Journal:  World J Surg       Date:  1980-07       Impact factor: 3.352

4.  Experimental hematogenous Candida endophthalmitis: diagnostic approaches.

Authors:  D K Henderson; J E Edwards; K Ishida; L B Guze
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

5.  Incidence and significance of opportunistic fungi in leukemia patients in India.

Authors:  C Rajendran; T K Basu; A Baby; S Kumari; T Verghese
Journal:  Mycopathologia       Date:  1992-08       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.